By fusing circular dichroism with high-resolution microspectroscopy and microscopic imaging, this cutting-edge technology is ...

The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...

ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading to ...

OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into agreements for the ...

For many years, cloned ponies have excelled in the prestigious equestrian sport of polo, and the sport has now taken a ...

The growth of the cell culture media market is driven by rising demand for biopharmaceuticals, vaccines, and cell-based therapies, fueled by advancem ...

KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months ...

Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

NEW YORK, NY, USA I 13, 2025 I Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel ...

Biotech and drug stocks, collectively, are down an average of 16% over the past three months. The closely watched XBI index ...

Protein Expression Technology MarketThe global protein expression technology market is set for significant expansion, ...